New Preclinical Results for Novel Class of Oral Anticoagulants Released at the 3rd International Conference on Heart & Brain

Verseon Corporation (AIM: VSN) will present a poster featuring new data for several promising oral anticoagulant drug candidates on February 25th at the 3rd International Conference on Heart & Brain (ICHB) in Paris. Verseon’s candidates represent a novel class of highly selective direct thrombin inhibitors (DTIs) with superior preclinical bleeding risk profiles when compared to those of the existing oral NOACs.

Verseon, a technology-based pharmaceutical company, uses its proprietary computational drug discovery platform to devise novel therapeutics for unmet medical needs. The Company’s new class of potent, highly selective DTIs has demonstrated excellent results in preclinical efficacy studies and has pharmacokinetic properties suitable for oral dosing.

“The new results we are presenting at ICHB include data from an additional comprehensive preclinical thrombosis model that further confirms the efficacy of Verseon’s drug candidates,” said Anirban Datta, Director of Discovery Biology at Verseon, “Our anticoagulants continue to show positive results as the program progresses.”

Latest Press Release on Heart Disease News

From 'the big one' to big relief for Adena Health heart attack patient

CHILLICOTHE, Ohio , April 23, 2024 /PRNewswire/ -- Jesse Patterson has always been more of a self-treatment type of guy when it comes to dealing with his health. So, when the nor...

11th International Conference on Interventional Cardiology

We are pleased to announce the 11th International Conference on Interventional Cardiology scheduled to take place on October 24-25 2024 in the picturesque city of Zurich Switzerland. This co...

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

AUSTIN, Texas , April 9, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center became the first in the nation to use...

Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System

SUNNYVALE, Calif. , March 18, 2024 /PRNewswire/ -- Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is please...

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

HANGZHOU, China , March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in...